FIBOCOM
22.6.2022 09:02:07 CEST | Business Wire | Press release
Fibocom (Stock Code: 300638), a global leading provider of IoT (Internet of Things) wireless solutions and wireless communication modules, announced the collaboration with Aetina Corporation , the provider of high-performance GPGPU and edge AI computing solutions, during Embedded World 2022. The joint effort aims to bring high-speed, ultra-reliable and low-latency 5G capacities, enabled by Fibocom’s 5G R16-compliant module FM160-EAU , to Aetina’s AN810-XNX AI edge computing platform, empowering robotics, UAV, industrial IoT, smart healthcare and more.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220622005419/en/
Combining Artificial Intelligence (AI) and IoT, dubbed AIoT, has opened up new possibilities for an era of smarter, faster decision-making. The rapid reaction time that AIoT offers is the result of shifting computing power to the edge. Based on NVIDIA Jetson Xavier NX, Aetina AN810-XNX is the world's leading platform for high-performance and energy-efficient AI computing. This edge computing platform fully supports M.2 device with extension slot, that assist developers expand their systems communication ability, I/O connectivity flexibly and quickly.
5G allows AIoT to overcome the data-transmission bottleneck, while analyzing and learning from data with rapid precision. Compliant with 3GPP Release16 (R16) standards, Fibocom FM160-EAU is a high-performance 5G M.2 module supporting NR Carrier Aggregation (CA), which optimizes 5G user experience with lightning-fast speed, extended coverage, boosted throughput and increased capacity. Embedded in Aetina AN810-XNX AI edge computing platform, FM160-EAU delivers enhanced 5G R16 capabilities to the edge, allowing businesses and industry benefit from intelligent and autonomous decision-making.
Moving forward, Fibocom and Aetina will deepens relationship, optimizing AI edge computing solutions based on Nvidia Jetson AGX Orin platform with high-performance 5G module featuring latest 3GPP standards. In collaboration with industry partners, Fibocom and Aetina are committed to enhance the development of 5G AIoT.
“Aetina has been building a wide and strong ecosystem network in global edge AI industry,” said Austin Lin, Jetson Series Product Division Head, Aetina. “This partnership with Fibocom benefits our clients with their growing demand of developing reliable AI platforms with real-time connectivity at the edge.”
“Our collaboration with Aetina reflects Fibocom’s commitment to building out the AIoT world,” said Simon Tao, General Manager of MBB Product Management Dept., Fibocom. “By bringing 5G capacities to the edge, AIoT can deliver on the full promise of its potential, ushering in a new era of massive connectivity that will revolutionize how we live, work and play.”
About Aetina
Aetina Corporation, founded in 2012 in Taipei, Taiwan, is a leading provider of high-performance GPGPU and Jetson edge AI computing solutions for embedded applications. With a focus on the industrial market, we provide industrial components and longevity services, and we are also an integrator in the AIoT market, easing customer pain points by offering smart, innovative, and reliable GPU solutions that satisfy their needs.
About Fibocom
Fibocom is a leading global provider of wireless communication modules and solutions in the sector of IoT (Internet of Things), as well as the first stock-listed (Stock Code:300638) wireless module provider in China. We provide end-to-end IoT wireless communication solutions for telecom operators, IoT equipment manufacturers, and IoT system integrators. With over two decades' engagement in M2M and IoT communication technology and extensive expertise, we are capable of independently developing high-performance wireless communication modules including 5G, LTE/LTE-A, NB-IoT/LTE-M, Android Smart, Automotive, WCDMA/HSPA(+), GSM/GPRS, Wi-Fi, GNSS, etc. Besides reliable, convenient, safe and intelligent IoT communication solutions for almost all vertical industries, we are also geared to customize the best and optimal IoT modules and solutions catering to your special requirements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220622005419/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release
The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release
Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom